|
KR102727059B1
(ko)
|
2015-02-16 |
2024-11-05 |
더 유니버서티 어브 퀸슬랜드 |
설포닐우레아와 관련 화합물 및 그 용도
|
|
US10521025B2
(en)
|
2015-10-20 |
2019-12-31 |
Magic Leap, Inc. |
Selecting virtual objects in a three-dimensional space
|
|
EP4418070A3
(en)
|
2016-03-31 |
2024-11-13 |
Magic Leap, Inc. |
Interactions with 3d virtual objects using poses and multiple-dof controllers
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
US11465992B2
(en)
*
|
2017-07-07 |
2022-10-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
RS65492B1
(sr)
|
2017-07-24 |
2024-05-31 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
|
|
ES2949404T3
(es)
*
|
2017-07-24 |
2023-09-28 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
US11542255B2
(en)
|
2017-08-15 |
2023-01-03 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
|
|
TW201910316A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
ES2927851T3
(es)
*
|
2017-10-17 |
2022-11-11 |
Novartis Ag |
Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
CN111315733A
(zh)
|
2017-11-09 |
2020-06-19 |
英夫拉索姆有限公司 |
新颖磺酰胺甲酰胺化合物
|
|
EP3759073A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
US11530200B2
(en)
|
2018-03-02 |
2022-12-20 |
Inflazome Limited |
Compounds
|
|
US11905252B2
(en)
|
2018-03-02 |
2024-02-20 |
Inflazome Limited |
Compounds
|
|
US20200399242A1
(en)
*
|
2018-03-02 |
2020-12-24 |
Inflazome Limited |
Novel compounds
|
|
WO2019166629A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166628A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
JP2021522349A
(ja)
|
2018-05-04 |
2021-08-30 |
インフレイゾーム リミテッド |
新規な化合物
|
|
CN113613721A
(zh)
*
|
2018-07-03 |
2021-11-05 |
诺华股份有限公司 |
Nlrp调节剂
|
|
CN112654350A
(zh)
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
AU2019306658A1
(en)
|
2018-07-20 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
EP3823726A1
(en)
|
2018-07-20 |
2021-05-26 |
F. Hoffmann-La Roche SA |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
AU2019322546A1
(en)
|
2018-08-15 |
2021-03-04 |
Inflazome Limited |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
US20220387397A1
(en)
*
|
2018-10-24 |
2022-12-08 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
WO2020102100A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
ES2974842T3
(es)
*
|
2018-11-13 |
2024-07-01 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
|
|
WO2020102574A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
EP3914583A1
(en)
*
|
2019-01-22 |
2021-12-01 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
EP3983388A1
(en)
*
|
2019-06-12 |
2022-04-20 |
Nodthera Limited |
Sulfonamide derivatives and uses thereof
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|
|
AU2020314186A1
(en)
*
|
2019-07-17 |
2022-02-24 |
Zomagen Biosciences Ltd |
NLRP3 modulators
|
|
US12466800B2
(en)
|
2019-07-17 |
2025-11-11 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS)
|
|
WO2021032588A1
(en)
|
2019-08-16 |
2021-02-25 |
Inflazome Limited |
Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
|
|
US20220289692A1
(en)
|
2019-09-06 |
2022-09-15 |
Inflazome Limited |
Nlrp3 inhibitors
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
MX2022011576A
(es)
|
2020-03-16 |
2022-10-18 |
Zomagen Biosciences Ltd |
Moduladores de nlrp3.
|
|
CN115551512A
(zh)
*
|
2020-03-19 |
2022-12-30 |
南洋理工大学 |
包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途
|
|
JP7738910B2
(ja)
|
2020-03-27 |
2025-09-16 |
テンヴィー・セラピューティクス，インコーポレーテッド |
置換ピリダジン化合物
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
EP4166541A4
(en)
|
2020-06-11 |
2024-09-04 |
Cisen Pharmaceutical Co.,Ltd |
Dimethylsulfoximine derivative
|
|
CN115768754B
(zh)
|
2020-06-19 |
2025-09-05 |
Ac免疫有限公司 |
调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
WO2022230912A1
(ja)
|
2021-04-28 |
2022-11-03 |
アステラス製薬株式会社 |
置換トリアジン化合物
|
|
IL310264A
(en)
|
2021-07-21 |
2024-03-01 |
Nico Therapeutics Inc |
Annulated pyridazine compound
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
KR20250036233A
(ko)
|
2022-07-14 |
2025-03-13 |
에이씨 이뮨 에스에이 |
Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
|
|
JP2025526423A
(ja)
|
2022-07-28 |
2025-08-13 |
エーシー・イミューン・エス・アー |
新規化合物
|
|
WO2024090469A1
(ja)
|
2022-10-26 |
2024-05-02 |
アステラス製薬株式会社 |
縮環ピリダジン誘導体
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
AU2024238394A1
(en)
*
|
2023-03-17 |
2025-10-30 |
Ventus Therapeutics U.S., Inc. |
Amide derivatives for inhibiting nlrp3 and uses thereof
|
|
WO2024249539A1
(en)
|
2023-06-02 |
2024-12-05 |
Merck Sharp & Dohme Llc |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|